ArticleDiabetes2016
Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes.
Article in Diabetes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Genetic Variants of the Human Thiamine Transporter (International journal of molecular sciences · 2025Article
- Genetic Variants Influence the Development of Diabetic Neuropathy.International journal of molecular sciences · 2024Review
- Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.Biomedicines · 2023Article
- Correlation between diabetic retinopathy and diabetic nephropathy: a two-sample Mendelian randomization study.Frontiers in endocrinology · 2023Article
- Genetic and epigenetic background of diabetic kidney disease.Frontiers in endocrinology · 2023Review
- Multiomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy.Translational cancer research · 2022Article
- The Heritability of Kidney Function Using an Older Australian Twin Population.Kidney international reports · 2022Article
- The Role of Biofactors in Diabetic Microvascular Complications.Current diabetes reviews · 2022Article
- Thiamine and diabetes: back to the future?Acta diabetologica · 2021Article
- Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes.Human molecular genetics · 2021Article
- Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules.BMC endocrine disorders · 2021Article
- Reduced Thiamine Availability and Hyperglycemia Impair Thiamine Transport in Renal Glomerular Cells through Modulation of Thiamine Transporter 2.Biomedicines · 2021Article
- What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs.Journal of diabetes research · 2021Review
- Blood thiamine pyrophosphate concentration and its correlation with the stage of diabetic retinopathy.International ophthalmology · 2020Article
- Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier.Acta diabetologica · 2020Article
- The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial.Journal of clinical medicine · 2020Article
- Unraveling the role of genetics in the pathogenesis of diabetic retinopathy.Eye (London, England) · 2019Review
- Progress in Defining the Genetic Basis of Diabetic Complications.Current diabetes reports · 2017Review
- Genetics: Risk of microvascular complications of T1DM.Nature reviews. Endocrinology · 2016Article
- Thiamine transporter 2 is involved in high glucose-induced damage and altered thiamine availability in cell models of diabetic retinopathy.Diabetes & vascular disease researchArticle
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 5 countries.
Funding
Abstract
The risk of long-term diabetes complications is not fully explained by diabetes duration or long-term glycemic exposure, suggesting the involvement of genetic factors. Because thiamine regulates intracellular glucose metabolism and corrects for multiple damaging effects of high glucose, we hypothesized that variants in specific thiamine transporters are associated with risk of severe retinopathy and/or severe nephropathy because they modify an individual's ability to achieve sufficiently high intracellular thiamine levels. We tested 134 single nucleotide polymorphisms (SNPs) in two thiamine transporters (SLC19A2/3) and their transcription factors (SP1/2) for an association with severe retinopathy or nephropathy or their combination in the FinnDiane cohort. Subsequently, the results were examined for replication in the DCCT/EDIC and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) cohorts. We found two SNPs in strong linkage disequilibrium in the SLC19A3 locus associated with a reduced rate of severe retinopathy and the combined phenotype of severe retinopathy and end-stage renal disease. The association for the combined phenotype reached genome-wide significance in a meta-analysis that included the WESDR cohort. These findings suggest that genetic variations in SLC19A3 play an important role in the pathogenesis of severe diabetic retinopathy and nephropathy and may explain why some individuals with type 1 diabetes are less prone than others to develop microvascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.